在阿尔茨海默病中使用调解探索因果性肠-大脑轴 门德尔的随机化分析
1Department of Traditional Chinese Medicine, The Second Hospital of Shandong University, Jinan, China.
Journal of Alzheimer's disease : JAD
|July 16, 2025
概括
这项研究揭示了与阿尔茨海默氏病 (AD) 有因果关系的四种肠道微生物群-大脑结构途径. 这些发现为了解阿尔茨海默氏症和通过探索阿尔茨海默氏症的肠-大脑轴开发治疗方法提供了新的目标.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其原因尚不清楚.
- 肠道微生物群失衡可能会通过增加肠道透性,血脑屏障功能受损和神经炎症影响AD.
- 对阿尔茨海默病的肠-大脑轴的观察性研究受到混因素和反向因果关系的限制.
研究的目的:
- 调查肠道微生物群,脑成像衍生的表型 (IDP) 和AD之间的因果关系.
- 为了确定与阿尔茨海默氏症病原发生有关的特定肠-大脑轴.
- 利用调解 门德尔的随机化分析来进行可靠的因果推断.
主要方法:
- 使用大规模的全基因组关联研究 (GWAS) 数据进行了三阶段的门德尔随机化分析.
- 检查了412种肠道微生物群和920种肠道虫对阿尔茨海默病的因果关系.
- 采用逆方差加权方法,结合来自多个大型队列的数据.
主要成果:
- 确定了12条肠道微生物的代谢途径和32种与AD相关的因果关系.
- 发现29名境内流离失所者与阿尔茨海默病有潜在的因果关系.
- 揭示了四个特定的肠-大脑轴:布蒂里维布里奥-大脑干-AD,拉克诺斯皮拉菌-大脑干-AD,PEPTIDOGLYCANSYN通路-L1外部囊左AD和TCA循环通路-L1外部囊左AD.
结论:
- 这项研究确定了四个新的肠道微生物群-大脑结构轴与阿尔茨海默病有因果关系.
- 提供了关于AD病变发生的肠-大脑轴机制的重要见解.
- 突出了阿尔茨海默病干预措施的潜在新型治疗目标.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.1K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
相关概念视频
Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
